Form 4: RAPT Therapeutics CEO Acquires 1,746,000 Stock Options

RAPT Therapeutics CEO, Brian Russell Wong, was granted 1,746,000 stock options on January 30, 2025, according to a recent SEC filing.

Summary

• Brian Russell Wong, the President and CEO of RAPT Therapeutics, acquired 1,746,000 employee stock options on January 30, 2025.
• The exercise price of these options is $1.14 per share.
• The options vest monthly over a four-year period, with 1/48th of the shares vesting each month starting January 1, 2025.
• The options expire on January 29, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotech industry.
• The vesting schedule of 1/48th per month is a typical vesting schedule for stock options.
• The 10-year expiration period is also a common practice.

Stakeholder Impact

• The stock option grant could positively impact shareholder value if the CEO successfully executes the company's strategy.
• The vesting schedule encourages long-term commitment from the CEO, which is beneficial for all stakeholders.

Key Dates

Keywords

stock options, executive compensation, insider trading, SEC Form 4, RAPT Therapeutics, Brian Russell Wong